BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25897893)

  • 1. LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.
    Hong CS; Ho W; Zhang C; Yang C; Elder JB; Zhuang Z
    Cancer Biol Ther; 2015; 16(6):821-33. PubMed ID: 25897893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma.
    Gordon IK; Lu J; Graves CA; Huntoon K; Frerich JM; Hanson RH; Wang X; Hong CS; Ho W; Feldman MJ; Ikejiri B; Bisht K; Chen XS; Tandle A; Yang C; Arscott WT; Ye D; Heiss JD; Lonser RR; Camphausen K; Zhuang Z
    Mol Cancer Ther; 2015 Jul; 14(7):1540-1547. PubMed ID: 25939762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.
    Zhang C; Hong CS; Hu X; Yang C; Wang H; Zhu D; Moon S; Dmitriev P; Lu J; Chiang J; Zhuang Z; Zhou Y
    Cell Cycle; 2015; 14(13):2100-8. PubMed ID: 25942376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair.
    Lv P; Wang Y; Ma J; Wang Z; Li JL; Hong CS; Zhuang Z; Zeng YX
    Oncotarget; 2014 Sep; 5(17):7512-24. PubMed ID: 25245035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Protein Phosphatase 2A Sensitizes Mucoepidermoid Carcinoma to Chemotherapy via the PI3K-AKT Pathway in Response to Insulin Stimulus.
    Liu L; Wang H; Cui J; Zhang Q; Zhang W; Xu W; Lu H; Liu S; Shen S; Fang F; Li L; Yang W; Zhuang Z; Li J
    Cell Physiol Biochem; 2018; 50(1):317-331. PubMed ID: 30282066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.
    Hao S; Song H; Zhang W; Seldomridge A; Jung J; Giles AJ; Hutchinson MK; Cao X; Colwell N; Lita A; Larion M; Maric D; Abu-Asab M; Quezado M; Kramp T; Camphausen K; Zhuang Z; Gilbert MR; Park DM
    Neuro Oncol; 2018 May; 20(6):799-809. PubMed ID: 29294092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation.
    Gao S; Shan L; Zhang M; Wang Y; Zhan X; Yin Y; Jiang Z; Tao X; Li X; Ye M; Liu Y
    Cell Oncol (Dordr); 2022 Dec; 45(6):1203-1215. PubMed ID: 36136269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.
    Chang KE; Wei BR; Madigan JP; Hall MD; Simpson RM; Zhuang Z; Gottesman MM
    Mol Cancer Ther; 2015 Jan; 14(1):90-100. PubMed ID: 25376608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells.
    Ho WS; Feldman MJ; Maric D; Amable L; Hall MD; Feldman GM; Ray-Chaudhury A; Lizak MJ; Vera JC; Robison RA; Zhuang Z; Heiss JD
    Oncotarget; 2016 Mar; 7(11):12447-63. PubMed ID: 26799670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic relevance of the protein phosphatase 2A in cancer.
    Cunningham CE; Li S; Vizeacoumar FS; Bhanumathy KK; Lee JS; Parameswaran S; Furber L; Abuhussein O; Paul JM; McDonald M; Templeton SD; Shukla H; El Zawily AM; Boyd F; Alli N; Mousseau DD; Geyer R; Bonham K; Anderson DH; Yan J; Yu-Lee LY; Weaver BA; Uppalapati M; Ruppin E; Sablina A; Freywald A; Vizeacoumar FJ
    Oncotarget; 2016 Sep; 7(38):61544-61561. PubMed ID: 27557495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.
    Wei D; Parsels LA; Karnak D; Davis MA; Parsels JD; Marsh AC; Zhao L; Maybaum J; Lawrence TS; Sun Y; Morgan MA
    Clin Cancer Res; 2013 Aug; 19(16):4422-32. PubMed ID: 23780887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PP2A for cancer therapeutic modulation.
    Ronk H; Rosenblum JS; Kung T; Zhuang Z
    Cancer Biol Med; 2022 Nov; 19(10):1428-39. PubMed ID: 36342229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
    Lee HJ; Hwang HI; Jang YJ
    Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.
    Ho WS; Sizdahkhani S; Hao S; Song H; Seldomridge A; Tandle A; Maric D; Kramp T; Lu R; Heiss JD; Camphausen K; Gilbert MR; Zhuang Z; Park DM
    Cancer Lett; 2018 Feb; 415():217-226. PubMed ID: 29199006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PP2A inhibition by LB-100 protects retinal pigment epithelium cells from UV radiation via activation of AMPK signaling.
    Li XF; Li SY; Dai CM; Li JC; Huang DR; Wang JY
    Biochem Biophys Res Commun; 2018 Nov; 506(1):73-80. PubMed ID: 30340831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
    Fu QH; Zhang Q; Zhang JY; Sun X; Lou Y; Li GG; Chen ZL; Bai XL; Liang TB
    Tumour Biol; 2016 Jun; 37(6):7277-86. PubMed ID: 26666823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
    Mirzapoiazova T; Xiao G; Mambetsariev B; Nasser MW; Miaou E; Singhal SS; Srivastava S; Mambetsariev I; Nelson MS; Nam A; Behal A; Arvanitis LD; Atri P; Muschen M; Tissot FLH; Miser J; Kovach JS; Sattler M; Batra SK; Kulkarni P; Salgia R
    Mol Cancer Ther; 2021 Oct; 20(10):1820-1835. PubMed ID: 34253596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL
    Lai D; Chen M; Su J; Liu X; Rothe K; Hu K; Forrest DL; Eaves CJ; Morin GB; Jiang X
    Sci Transl Med; 2018 Feb; 10(427):. PubMed ID: 29437150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
    Kauko O; Imanishi SY; Kulesskiy E; Yetukuri L; Laajala TD; Sharma M; Pavic K; Aakula A; Rupp C; Jumppanen M; Haapaniemi P; Ruan L; Yadav B; Suni V; Varila T; Corthals GL; Reimand J; Wennerberg K; Aittokallio T; Westermarck J
    J Biol Chem; 2020 Mar; 295(13):4194-4211. PubMed ID: 32071079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.